Unlike indistinctive cytotoxicity from conventional chemotherapy drugs, apatinib was an antiangiogenic agent, which highly selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase, mediating the growth of the tumor by inhibiting angiogenesis (33). The gene discussed is KDR; the disease is neoplasm.